Record overview
Status and phase
Status: NOT_YET_RECRUITING
Phase: PHASE2
Sponsor: Xijing Hospital
Condition: Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer
NCT07466303
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal
Stopped reason
Context when available
No stop reason available in the current public record.